Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Glucagon; related peptides
Reexamination Certificate
2007-02-13
2007-02-13
Weber, Jon (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Glucagon; related peptides
C530S394000, C530S402000, C424S192100, C435S069700
Reexamination Certificate
active
10378094
ABSTRACT:
The present invention discloses fusion proteins comprising transferrin, lactoferrin or melanotransferrin fused to glucagon-like peptide 1 (GLP-1). In one embodiment of the invention, the fusion protein displays increased serum half-life as compared to a GLP-1 peptide in an unfused state. The invention includes a pharmaceutical composition comprising the GLP-1 fusion protein of the invention and a carrier. The fusion protein of the invention can be administered to a subject for treatment of diseases or conditions treatable by GLP-1, including, but not limited to, diabetes, obesity, congestive heart failure and inflammatory bowel syndrome.
REFERENCES:
patent: 4289689 (1981-09-01), Friesen et al.
patent: 4738931 (1988-04-01), Sugano et al.
patent: 4816449 (1989-03-01), Hahn
patent: 5026651 (1991-06-01), Bowman et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5262177 (1993-11-01), Brown et al.
patent: 5442043 (1995-08-01), Fukuta et al.
patent: 5455030 (1995-10-01), Ladner et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5518889 (1996-05-01), Ladner et al.
patent: 5571691 (1996-11-01), Conneely et al.
patent: 5571896 (1996-11-01), Conneely et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5672683 (1997-09-01), Friden et al.
patent: 5817789 (1998-10-01), Heartlein et al.
patent: 5876969 (1999-03-01), Fleer et al.
patent: 5948613 (1999-09-01), Teng et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 5986067 (1999-11-01), Funk et al.
patent: 6027921 (2000-02-01), Heartlein et al.
patent: 6066469 (2000-05-01), Kruzel et al.
patent: 6069193 (2000-05-01), Vargas et al.
patent: 6245737 (2001-06-01), Boyd et al.
patent: 6262026 (2001-07-01), Heartlein et al.
patent: 6277817 (2001-08-01), Kruzel et al.
patent: 6348568 (2002-02-01), Barney et al.
patent: 6380362 (2002-04-01), Watson et al.
patent: 6420346 (2002-07-01), Karin
patent: 6455687 (2002-09-01), Kruzel et al.
patent: 6458924 (2002-10-01), Knudsen et al.
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 2003/0199672 (2003-10-01), Knudsen et al.
patent: 2003/0221201 (2003-11-01), Prior et al.
patent: 2003/0226155 (2003-12-01), Sadeghi et al.
patent: 2004/0023334 (2004-02-01), Prior
patent: 0314317 (1989-05-01), None
patent: 0413662 (1991-02-01), None
patent: 0978565 (2000-02-01), None
patent: 1408050 (2004-04-01), None
patent: WO 95/02421 (1995-01-01), None
patent: WO 99/43707 (1999-09-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO 01/04156 (2001-01-01), None
patent: WO 01/36643 (2001-05-01), None
patent: 01/46254 (2001-06-01), None
patent: WO 01/79258 (2001-10-01), None
patent: WO 02/46227 (2002-06-01), None
patent: WO 02/46227 (2002-06-01), None
patent: WO 03/016349 (2003-02-01), None
patent: WO 03/020746 (2003-03-01), None
patent: WO 03/082898 (2003-10-01), None
patent: WO 2004/019872 (2004-03-01), None
patent: WO 2004/020404 (2004-03-01), None
patent: WO 2004/020405 (2004-03-01), None
patent: WO 2004/020454 (2004-03-01), None
patent: WO 2004/020588 (2004-03-01), None
patent: WO 2004/078777 (2004-09-01), None
Xiao et al. (Mar. 2001) Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry, vol. 40, No. 9, pp. 2860-2869.
Xia et al. (2000) Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. vol. 295, No. 2, pp. 594-600.
Adrian et al. “Human transferrin: Expression and iron modulation of chimeric genes intransgenic mice” J. Biol. Chem. 265(22): 13344, 1990.
Gallop et al. “Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries” J. Med. Chem. 37(9): 1234, 1994.
Gallwitz B et al. (1996) “GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1” Regul Pept. 63(1):17-22, 1996.
MacGillivray et al. “The primary structure of human serum transferrin” J. Biol. Chem. 258(6): 3543, 1983.
Salmon et al. “Production of human lactoferrin in transgenic tobacco plants” Protein Exp. Purif. 13: 127, 1998.
Ward et al. “A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic” Biotechnology 13:498, 1995.
Batra et al., “Single Chain Immunotoxins Directed at the Human Transferrin Receptor Containing Pseudomonas Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT 388-Anti-TFR(Fv)”, Mol. Cell. Biol., 11:2200-2205, 1991.
Brinkman et al., “A recombinant immunotoxiin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form ofPseudomonasexotoxin”, Prc. Natl. Sci. Acad. Sci. USA, vol. 90, pp. 547-551, Jan. 1993.
Chaudhary et al., “A recombinant immunotoxin consisting of two antibody variable domains fused toPseudomonasexotoxin”, Nature, 339:394-397, 1989.
Database A GENESEQ (Compugen LTD), Accession No. AAR66492, (Jacobs et al), Nov. 25, 1994.
Hoo et al., “Characterization of a single-chain T-cell receptor expressed inEscherichia coli”, Proc. Nat. Acad. Sci. USA, 89:4759-4763, 1993.
Huston et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli”, Proc. Nat. Acad. Sci. USA; 85 (16):5879-5883, 1988.
Liang et al., “Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachetin”, Biochem Biophys Res. Comm. 137:847-854, 1986.
Nicholls, “Characterization of Single-chain Antibody (sFv)-Toxin Fusion Proteins Produced in Vitro in Rabbit Reticulocyte Lysate”, J. Biological Chem., 268: 5302-5308, 1993.
Prince et al., “Efficient Endocytosis of the Cystic Fibrosis Transmembrane Conductance Regulator Requires a Tyrosine-Based signal, ” J Biol Chem 274(6):3602-3609, 1999.
Sheridan et al., “Solid-phase Synthesis and Cyclization of a Large Branched Peptide from IgG Fc with Affinity for FcRI”, J. Pept. Sci, 1999, 5(12):555-562.
Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells”, EMBO J., 10(12):3655-3659, 1991.
Arndt, T., “Carbohydrate-Deficient Transferrin as a Marker of Chronic Alcohol Abuse: A Critical Review of Preanalysis, Analysis, and Interpretation,”Clinical Chemistry47:13-27, 2001.
Ali et al., “Transferrin Trojan Horses as a Rational Approach for the Biological Delivery of Therapeutic Peptide Domains,”J Biol Chem274(34):24066-24073, 1999.
Newton et al., “Antitransferrin Receptor antibody-RNase Fusion Protein Expressed in the Mammary Gland of transgenic mice,”J Immunological Methods231:159-167, 1999.
Park et al., “Production and characterization of Fusion Proteins Containing Transferrin and Nerve Growth Factor,”J Drug Targeting6(1):53-64, 1998.
Prince et al., “Efficient Endocytosis of the Cystic Fibrosis Transmembrane Conductance Regulator Requires a Tyrosine-Based signal,”J Biol Chem274(6):3602-3609, 1999.
Regoeczi et al., “Rat Aglycotransferrin and Human Monoglycotransferrin: Production and Metabolic Properties,”Archives of Biochemistry and Biophysics268(2): 637-642, 1989.
Shin et al., “Transferrin-Antibody Fusion Proteins are Effective in Brain Targeting,”Proc Natl Acad Sci USA92:2820-2824, 1995.
Bradley et al., “Identification of the cellular receptor for anthrax toxin,”Nature414:225-229, 2001.
Bradley et al., “Anthrax toxin receptor proteins,”Biochemical Pharmacology65:309-314, 2003.
Cha et al., “Receptor-based antidote for diphtheria,”Infection and Immunity70(5):2344-2350, 2002.
Drucker, “Biological actions and therapeutic potential of the glucagon-like peptides,”Gastroenterology122:531-544, 2002.
Kozaki et al., “Characterization ofClostridium botulinumtype B neurotoxin associated wi
BioRexis Technology, Inc.
Cooley Godward LLP.
Liu Samuel W.
Weber Jon
LandOfFree
Modified transferrin fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified transferrin fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified transferrin fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3890443